{"raw_mentions": "For example, the compounds of this invention possess potent NET, DAT, & SERT IC50/Ki values of less than 200 nM."}
{"final_json": [{"molecule_name": null, "protein_target_name": "NET, DAT, & SERT", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50/Ki", "value": "<200", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n20 \u03bcl/well of a 2\u00d7 membrane preparation (15 ug/ml in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) and 20 \u03bcl/well of a 2\u00d7 radioligand solution (520 pM [<sup>125</sup>I]RTI-55 in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) were added to each well and the reaction incubated for 1 Hour at room temperature.\n20 ul/well of a 2\u00d7 membrane preparation (12.5 \u03bcg/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4\u00b0 C.) and 20 \u03bcl/well of a 2\u00d7 radioligand solution (250 pM [<sup>125</sup>I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4\u00b0 C.) were added to the well and the reaction incubated for 1 Hour at room temperature.\n50 \u03bcl/well of a 2\u00d7 membrane preparation (0.4 mg/ml in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) and 50 \u03bcl/well of a 2\u00d7 radioligand solution (4 nM [<sup>3</sup>H]nisoxetine in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) were added to the well and the reaction incubated for 1 Hour at room temperature."}
{"final_json": [{"molecule_name": "[<sup>125</sup>I]RTI-55", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "520", "unit": "pM"}, {"molecule_name": "[<sup>125</sup>I]RTI-55", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "250", "unit": "pM"}, {"molecule_name": "[<sup>3</sup>H]nisoxetine", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "4", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe specific binding was calculated by subtracting the value of the non-specific binding from that of the total binding in each sample is not relevant, however: \nTABLE 1 contains: SERT2 nMFluoxetine,Tris, 5010 minutes[<sup>3</sup>H]Citalopram10NaCl, 120at 4\u00b0 C.KCl, 5\nTABLE 1 contains: DAT0.1 nMGBR-12935,Sodium10 minutes[<sup>125</sup>I]RTI-5510phosphateat 4\u00b0 C.(+0.5 \u03bcMbuffer, 30citalopram)\nTABLE 1 contains: NET5 nMReboxetine,Tris, 5020 minutes[<sup>3</sup>H]-Nisoxetine10NaCl, 300at 4\u00b0 C.KCl, 5\nTABLE 2 contains: 1 (+)-enantiomer1.830.826.0752611131 \nTABLE 2 contains: 1 (\u2212)-enantiomer4.2104.64.841303313"}
{"final_json": [{"molecule_name": "Fluoxetine", "protein_target_name": "SERT2", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": "nM"}, {"molecule_name": "GBR-12935", "protein_target_name": "DAT", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.1", "unit": "nM"}, {"molecule_name": "Reboxetine", "protein_target_name": "NET5", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "5", "unit": "nM"}, {"molecule_name": "1 (+)-enantiomer", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1.83", "unit": null}, {"molecule_name": "1 (\u2212)-enantiomer", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "4.21", "unit": null}]}
